Compare Hilton Hotels Corporation Common Stock (HLT) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hilton Hotels Corporation Common Stock vs Mesoblast Limited — how do they compare? Hilton Hotels Corporation Common Stock trades at $319 (market cap $70.00B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Hilton Hotels Corporation Common Stock is far larger — about 32.4× Mesoblast Limited's market cap, and Hilton Hotels Corporation Common Stock pays a 0.19% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| HLT | MESO | |
|---|---|---|
Market Cap | $70.00B | $2.16B |
Sector | Consumer Cyclical | Technology |
52-Week High | $350.22 | $20.96 |
52-Week Low | $256.75 | $12.88 |
Enterprise Value | $83.01B | $2.17B |
Dividend Yield | 0.19% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.
Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Hilton Hotels Corporation Common Stock
Hilton Worldwide Holdings operates 1,074,791 rooms across its 18 brands addressing the midscale through luxury segments as of Dec. 31, 2021. Hampton and Hilton are the two largest brands by total room count at 28% and 21%, respectively, as of Dec. 31, 2021. Recent brands launched over the last few years include Home2, Curio, Canopy, Tru, and Tempo. Managed and franchised represent the vast majority of adjusted EBITDA, predominantly from the Americas regions.
Read more on HLT →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
